Great posts Kelt, Seel, and Dyna. I was trying to put the starting dosage and escalations for cohort 2 and 3 in perspective, but it is hard to do because Kevetrin is just different. Where other drugs might take X to start to show efficacy, for all we know kevetrin could start to see results much, much sooner, and i think we have hints of this as P21 testing has been ongoing at these "low" doses.

We are just breaking new ground as we go here, but so far so good. And an excited Dr Menon at todays conference really tells me all i need to know about what to expect in the upcoming cohorts.